Mass tort litigation creates a unique financial trap for plaintiffs’ attorneys: they front millions in case costs while waiting years—sometimes a decade or more—for any revenue to materialize. A lawyer handling a pharmaceutical mass tort might spend $50,000 to $200,000 per case just on expert witnesses, medical records acquisition, and deposition costs, then wait five to ten years for settlement or verdict. During that entire period, the firm receives no income from the case, yet continues paying staff, rent, and operating expenses from other sources. This mismatch between spending and revenue has forced dozens of mass tort firms into serious debt, refinancing, or closure.
The pressure accelerates when cases stall. If a judge delays trial, appeals drag on, or settlement negotiations freeze, the cost burden compounds while revenue remains zero. Lawyers cannot pass these expenses to plaintiffs under ethical rules—the contingency fee structure means the firm absorbs all costs regardless of outcome. A single case loss or settlement delay can destabilize a firm’s entire balance sheet.
Table of Contents
- How Many Years Do Mass Tort Cases Actually Take?
- The Upfront Cost Burden Mass Tort Lawyers Carry
- Why Contingency Fee Arrangements Create Debt Risk
- Managing Cash Flow During Multi-Year Litigation
- When Cases Settle Late or Lose Entirely
- How Firm Size Affects Debt Vulnerability
- What Happens When Debt Spirals
- Frequently Asked Questions
How Many Years Do Mass Tort Cases Actually Take?
mass tort cases rarely resolve in under three years and frequently stretch to seven or more. The 2006 Vioxx litigation took over a decade to settle completely. Talc litigation cases filed in 2009 are still resolving in 2024 and 2025. asbestos claims, depending on exposure location and health outcome, can remain active for 15+ years as claimants develop diseases years or decades after exposure.
This timeline isn’t arbitrary—it reflects the complexity of proving causation, the number of parties involved, and the courts’ crowded dockets. A single pharmaceutical case might require three expert reports, multiple rounds of discovery, depositions of plaintiffs and company executives, and motion practice before trial even begins. Meanwhile, the firm is paying expert witness fees, court reporters, and paralegal time from its operating budget. A mid-size firm might have 50 to 200 pending cases at various stages, meaning hundreds of thousands of dollars in unrecovered costs spread across years.
The Upfront Cost Burden Mass Tort Lawyers Carry
Unlike personal injury cases (a car accident) where a single client covers a focused investigation, mass tort litigation requires systemic infrastructure. Attorneys must hire medical experts to establish general causation (does the product cause the injury?), not just individual causation. A single pharmaceutical mass tort case might need a toxicologist, an epidemiologist, and a physician—costs easily exceeding $75,000 before trial. Filing in multiple jurisdictions compounds expenses.
A lead attorney coordinating cases across state courts pays filing fees, local counsel retainers, and state-specific expert fees in each venue. Asbestos litigation, which spans federal and state courts nationwide, forces firms to maintain relationships and advance costs in dozens of jurisdictions. One asbestos firm managing 500 claimants across 30 states reported frontline costs of $3 million annually before recovering a single settlement dollar—a burden smaller firms cannot sustain. The costs don’t end with experts. Firms must fund depositions (court reporters charge $200–$400 per day), medical record retrieval and review (which can cost $20,000–$50,000 for complex cases), and travel for trial preparation. If a case goes to trial, the expense spike is severe: expert testimony can run $10,000–$25,000 per expert, plus living expenses for the trial team.
Why Contingency Fee Arrangements Create Debt Risk
The contingency fee model—attorneys recover only if plaintiffs win or settle—transfers all financial risk to the law firm. If a case loses at trial, the firm writes off all costs and receives nothing. Unlike hourly billing, where the firm generates revenue regardless of outcome, contingency work creates a winner-take-most dynamic. A firm handling 100 cases might lose 20, settle 60 with modest recoveries, and get one major win that funds operations for two years. This uncertainty makes debt inevitable for growing firms. To expand case capacity, firms must borrow or invest equity to cover costs of new cases that may not settle for five years. A firm with good historical outcomes might secure a $5 million credit line to finance 50 new cases, betting that historical settlement rates hold.
But markets change. Juries become more skeptical of certain claims, judges rule against plaintiffs in key motions, or settlement negotiations stall. Firms that borrowed aggressively based on optimistic projections suddenly face negative cash flows. One notable example: a mid-size talc litigation firm borrowed $4 million in 2015 expecting major settlements by 2018. When trials resulted in defense verdicts and appellate courts ruled for defendants, the firm’s settlement timeline extended to 2022–2024. Interest on the debt accumulated, and the firm had to lay off staff and close satellite offices. The contingency fee that seemed prudent in 2015 became a liability in 2018.
Managing Cash Flow During Multi-Year Litigation
Profitable mass tort firms employ sophisticated cash management to survive the lag between spending and recovery. Many maintain a portfolio of older cases (settled or near-settlement) generating current revenue, balanced against newer cases (years from resolution) requiring current spending. This creates a “rolling revenue” model where settlements from 2018 cases fund costs of 2025 cases. Some firms sell portions of their expected settlements to lawsuit financiers—companies that purchase a percentage of future recovery in exchange for upfront capital. If a firm expects $3 million from a case expected to settle in two years, it might sell 20% of that expected recovery for $400,000 today. This transfers risk but also reduces final recovery.
Alternatively, firms secure litigation finance loans: lenders provide capital based on the firm’s portfolio, with repayment tied to settlement proceeds. Interest rates are typically 8–15% annually, which cuts into final plaintiff recoveries. The downside is that lawsuit financing costs money. If a firm borrows $500,000 at 12% annual interest to fund cases settling in four years, it will pay $240,000 in interest before recovery occurs. That cost is borne by clients if cases settle, or absorbed by the firm if they lose. Smaller firms often lack access to financing altogether, forcing them to slow case acquisition or operate on razor-thin margins.
When Cases Settle Late or Lose Entirely
A delayed settlement is nearly as damaging as a loss. If a case expected to settle in three years drags to five, the firm has already financed four years of costs and must fund year five entirely before any recovery. Pharmaceutical cases offer a stark example: firms handling cases tied to a drug’s removal from market (like Vioxx, withdrawn in 2004) waited until 2007 for the global settlement, then 2010–2015 for final distributions. Attorneys who advanced $300,000 per case in 2004–2006 didn’t recover funds until 2010 or later—a six-year lag during which interest accrued, staff costs escalated, and firm cash reserves depleted.
Case losses create irreversible damage. If a firm invests $150,000 in a mass tort case expecting a 70% settlement rate (based on historical data), but that case loses at trial, the $150,000 is gone. If the firm extrapolates 70% success across 100 cases and loses 40 instead of 30, it faces a $1.5 million shortfall. A firm with $8 million in annual revenue and $6 million in annual overhead suddenly cannot cover payroll. Several mass tort firms faced this scenario in 2020–2022 when COVID-delayed trials resolved and multiple cases lost unexpectedly.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
How Firm Size Affects Debt Vulnerability
Large national firms with diverse case portfolios absorb losses better. A firm with 500+ cases across multiple practice areas can absorb a 40% loss in one category if other categories perform well. They also access capital more easily: banks recognize large firms as creditworthy and offer favorable lending terms. In contrast, solo practitioners or small firms handling 30–50 cases live one major loss away from insolvency.
Small firms are also least able to afford litigation finance. A lender reviewing a 10-lawyer, 40-case firm sees higher risk than a 100-lawyer firm with 500 cases and 20 years of settlement history. Interest rates offered to small firms are often 15–20%, versus 8–12% for large firms. This gap means small firms pay proportionally more to access capital, reducing their competitive position. If a large firm and small firm both borrow $1 million to fund new cases, the large firm might pay $100,000 in year-one interest, while the small firm pays $150,000—a $50,000 structural disadvantage before any litigation outcome is known.
What Happens When Debt Spirals
Some mass tort firms have entered debt spirals that ended in closure or forced merger. A firm that borrowed $10 million in 2015 expecting strong talc settlements instead watched its settlement value decrease as juries skepticism grew and appellate courts ruled for defendants. By 2020, facing debt service of $1.5 million annually plus staff costs, the firm couldn’t meet obligations. Some negotiated with creditors to restructure debt.
Others were absorbed by larger competitors who assumed their debt in exchange for staff and cases. A small number simply closed, leaving clients without representation. The worst-case scenario is the loss-spiral: debt service consumes operating cash, so the firm cuts staff, which reduces case capacity and revenue potential, which increases debt burden proportionally. One prominent mass tort firm that filed for bankruptcy protection in 2018 cited exactly this cycle—debt grew to $8 million, payment obligations forced staff reductions, reduced capacity meant fewer cases and lower revenue, which made debt proportionally worse. The firm eventually reorganized but returned to practice at a fraction of its prior size.
Frequently Asked Questions
How much money do mass tort firms typically front per case?
Costs range from $25,000 for smaller personal injury cases to $200,000+ for complex pharmaceutical litigation requiring multiple expert witnesses, medical record acquisition, and deposition work.
Can firms pass litigation costs to clients under ethics rules?
No. Rules of Professional Conduct prohibit attorneys from requiring clients to reimburse litigation costs if the case is lost and the client receives nothing. Firms absorb all risk.
How long before a mass tort firm recovers its costs?
Typically 5–10 years or more. Pharmaceutical cases average 7–9 years; asbestos claims can remain active for 15+ years. During the entire period, firms receive no income from those cases.
What is lawsuit financing and how does it work?
Lawsuit financiers purchase a percentage of a firm’s expected settlement proceeds in exchange for upfront capital. A firm expecting $3 million in two years might sell 20% of that recovery for $400,000 today, reducing final client recovery by the finance cost and interest.
What percentage of mass tort cases settle versus go to trial?
Settlement rates vary by case type but average 60–80% across all mass tort categories. However, settlement value, timing, and predictability are lower in recent years as juries and appellate courts have become more skeptical of certain claims.
Why are smaller firms more vulnerable to debt than large firms?
Small firms have fewer cases to balance against losses and less access to capital at favorable rates. Banks charge 15–20% interest to small firms but 8–12% to large established firms, creating a structural cost disadvantage.
You Might Also Like
- Sally Beauty Battles Insurer Over Mass Tort Defense Costs
- Mayer Brown Rebuilds Mass Tort Team With WilmerHale Partner Hires
- Elizabeth Chamblee Burch Book Examines How Mass Tort Deals Really Work